Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written (signed) informed consent(s)
Inoperable and incurable, locally advanced, recurrent or metastatic NSCLC
Relapse following standard chemotherapy (combination chemotherapy such as two-drug combination chemotherapy, or a single-agent chemotherapy agent for elderly or poor performance status patients)
Age \>=18 years
ECOG performance status of 0 to 3
Recovered from the toxic effects of prior therapy
Able to comply with study and follow-up procedures
Able to take oral medication
Use of an effective means of contraception (for patients with reproductive potential)
Granulocyte count \>=1.0 x 10\^9/L
Platelet count \>=75 x 10\^9/L
Serum bilirubin \<1.5 x upper limit of normal (ULN)
SGOT (AST) \<2 x ULN unless elevation is clearly due to liver metastases; then SGOT (AST) must be \<5 x ULN
Serum creatinine \<=1.5 mg/dL
You may not be if
Any unstable systemic disease (including active infection, unstable angina, congestive heart failure, myocardial infarction within the last 6 months, hepatic, renal, or metabolic disease)
Prior therapy with any systemic HER1/EGFR small molecule inhibitor, including gefitinib (Iressa), erlotinib (Tarceva), or other investigational agents in this class
History of another malignancy in the past 2 years unless the malignancy has been adequately treated and is associated with a 5-year anticipated survival of \>=90%
Known central nervous system (CNS) metastases that have not yet been definitively treated with surgery and/or radiation or that are symptomatic or unstable
Nursing mothers or pregnant females
Clareo Health | A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
